Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Prostate

Retrieve available abstracts of 218 articles:
HTML format



Single Articles


    February 2022
  1. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2022;82:401-402.
    PubMed    


  2. URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
    Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
    Prostate. 2022;82:330-344.
    PubMed     Abstract available


    January 2022
  3. MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
    Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
    PubMed     Abstract available


  4. ZHU S, Zhang Z, Zhang H, Liu Z, et al
    DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
    PubMed     Abstract available


  5. ZHOU J, Chen H, Wu Y, Shi B, et al
    Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
    PubMed     Abstract available


  6. CAO Y, Song DY, Deville C, DeWeese TL, et al
    Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
    Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
    PubMed     Abstract available


  7. RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
    Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
    PubMed     Abstract available


  8. VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
    Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
    PubMed     Abstract available


    December 2021
  9. SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
    Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
    Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
    PubMed     Abstract available


  10. MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
    MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
    Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
    PubMed     Abstract available


  11. SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
    Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
    Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
    PubMed     Abstract available


  12. HE H, Han D, Xu F, Lyu J, et al
    How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
    Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
    PubMed     Abstract available


  13. URABE F, Miki K, Kimura T, Sasaki H, et al
    Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
    PubMed     Abstract available


  14. KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
    Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
    PubMed     Abstract available


  15. BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
    Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
    Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
    PubMed     Abstract available


  16. LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
    Metabolic syndrome and prostate cancer in Afro-Caribbean men.
    Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
    PubMed     Abstract available


  17. POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
    Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
    PubMed     Abstract available


  18. ZAREI A, Javid H, Sanjarian S, Senemar S, et al
    Metagenomics studies for the diagnosis and treatment of prostate cancer.
    Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
    PubMed     Abstract available


    November 2021
  19. NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
    Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
    PubMed     Abstract available


  20. VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
    Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
    PubMed     Abstract available


  21. PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
    Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
    PubMed     Abstract available


  22. PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
    Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
    PubMed     Abstract available


  23. NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
    Clinical and genomic features of SPOP-mutant prostate cancer.
    Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
    PubMed     Abstract available


  24. TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
    Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
    Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
    PubMed     Abstract available


  25. HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
    Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
    PubMed     Abstract available


  26. MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
    Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
    PubMed     Abstract available


    October 2021
  27. SHI Z, Lu L, Resurreccion WK, Yang W, et al
    Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
    PubMed     Abstract available


  28. PILLING A, Kim SH, Hwang C
    Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
    PubMed     Abstract available


  29. LUO LS, Jiang JF, Luan HH, Zi H, et al
    Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
    PubMed     Abstract available


  30. KIM S, Li L, Zhang J, Jiang C, et al
    Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
    PubMed     Abstract available


  31. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
    PubMed     Abstract available


  32. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
    PubMed     Abstract available


  33. IKEUCHI W, Wakita Y, Zhang G, Li C, et al
    AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
    PubMed     Abstract available


  34. JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
    Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
    PubMed     Abstract available


    September 2021
  35. YIN Y, Liu Q, Shao Y, He X, et al
    Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
    PubMed     Abstract available


  36. YU C, Niu L, Li L, Li T, et al
    Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
    PubMed     Abstract available


  37. YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
    Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
    PubMed     Abstract available


  38. YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
    Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
    Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
    PubMed     Abstract available


  39. HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
    SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
    PubMed     Abstract available


  40. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
    Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
    PubMed     Abstract available


  41. JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
    Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
    PubMed     Abstract available


  42. LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
    Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
    PubMed     Abstract available


  43. AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
    The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
    PubMed     Abstract available


  44. WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
    PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
    PubMed     Abstract available


  45. LIU Y, Dong Y, Liu J, Zhang X, et al
    Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
    PubMed     Abstract available


  46. CHHATRE S, Malkowicz SB, Jayadevappa R
    Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
    PubMed     Abstract available


  47. SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
    Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
    PubMed     Abstract available


  48. CHO MC, Yoo S, Choo MS, Son H, et al
    Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
    PubMed     Abstract available


  49. MANGOSH TL, Grabowska MM, Taylor DJ
    SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
    PubMed     Abstract available


  50. MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
    Pathological significance and prognostic role of LATS2 in prostate cancer.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
    PubMed     Abstract available


  51. MIYAHIRA AK, Soule HR
    The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
    PubMed     Abstract available


  52. SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
    Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
    PubMed     Abstract available


    August 2021
  53. LEDET EM, Sartor O
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.
    PubMed    


  54. DI MAIDA F, Grosso AA, Minervini A
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.
    PubMed    


  55. SHAO L, Wang J, Karatas O, Ittmann M, et al
    MEX3D is an oncogenic driver in prostate cancer.
    Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
    PubMed     Abstract available


  56. SUN BL
    Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
    PubMed     Abstract available


  57. WANG Z, Zhu S, Zhao J, Nie L, et al
    The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
    PubMed     Abstract available


  58. OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
    Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
    Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
    PubMed     Abstract available


  59. HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
    Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
    PubMed     Abstract available


  60. WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
    The effect of primary urological cancers on survival in men with secondary prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
    PubMed     Abstract available


  61. NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
    Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
    Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
    PubMed     Abstract available


    July 2021
  62. ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
    Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
    PubMed     Abstract available


  63. LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
    Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
    PubMed     Abstract available


  64. CAO Y, Zhang W, Li Y, Fu J, et al
    Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
    PubMed     Abstract available


  65. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
    Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
    PubMed     Abstract available


  66. CHAO OS, Goodman OB Jr
    DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
    PubMed     Abstract available


  67. EPSTEIN JI
    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.
    PubMed    


  68. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    PubMed     Abstract available


  69. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    PubMed     Abstract available


  70. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    PubMed     Abstract available


  71. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    PubMed     Abstract available


  72. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    PubMed     Abstract available


  73. CHEN DY, Su PJ, See LC, Liu JR, et al
    Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
    PubMed     Abstract available


  74. BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
    SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
    PubMed     Abstract available


    June 2021
  75. LV S, Pu X, Luo M, Wen H, et al
    Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
    PubMed     Abstract available


  76. WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
    Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
    PubMed     Abstract available


  77. LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
    Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
    PubMed     Abstract available


  78. BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
    Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
    Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
    PubMed     Abstract available


  79. NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
    PubMed     Abstract available


  80. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    PubMed     Abstract available


  81. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    PubMed     Abstract available


  82. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    PubMed     Abstract available


  83. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    PubMed     Abstract available


  84. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
    Prostate. 2021;81:443-451.
    PubMed     Abstract available


  85. CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
    Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
    Prostate. 2021;81:521-529.
    PubMed     Abstract available


  86. XIAO GQ, Ho G, Suen C, Hurth KM, et al
    Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Prostate. 2021;81:469-477.
    PubMed     Abstract available


    May 2021
  87. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    PubMed     Abstract available


  88. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    PubMed     Abstract available


  89. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    PubMed     Abstract available


  90. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    PubMed     Abstract available


  91. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    PubMed     Abstract available


  92. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    PubMed     Abstract available


  93. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.
    PubMed    


  94. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    PubMed     Abstract available


  95. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    PubMed     Abstract available


  96. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    PubMed     Abstract available


  97. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    PubMed     Abstract available


  98. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    PubMed     Abstract available


  99. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    PubMed     Abstract available


  100. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    PubMed     Abstract available


  101. WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
    The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
    Prostate. 2021;81:339-346.
    PubMed     Abstract available


  102. LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
    Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Prostate. 2021;81:318-325.
    PubMed     Abstract available


  103. ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
    Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Prostate. 2021;81:390-397.
    PubMed     Abstract available


    April 2021
  104. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed     Abstract available


  105. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed     Abstract available


  106. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed     Abstract available


  107. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed     Abstract available


  108. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed     Abstract available


  109. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed     Abstract available


  110. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed     Abstract available


  111. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    PubMed     Abstract available


  112. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    PubMed     Abstract available


  113. LEDET EM, Burgess EF, Sokolova AO, Jaeger EB, et al
    Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Prostate. 2021 Apr 1. doi: 10.1002/pros.24123.
    PubMed     Abstract available


    March 2021
  114. SABOL RA, Ledet EM, Jaeger E, Hatton W, et al
    Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Prostate. 2021 Mar 24. doi: 10.1002/pros.24120.
    PubMed     Abstract available


  115. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    What are survivorship care plans failing to tell men after prostate cancer treatment?
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24116.
    PubMed     Abstract available


  116. GRAHAM LS, True LD, Gulati R, Schade GR, et al
    Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24118.
    PubMed     Abstract available


  117. LEHTO TK, Sturenberg C, Malen A, Erickson AM, et al
    Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24108.
    PubMed     Abstract available


  118. LIOTTI A, La Civita E, Cennamo M, Crocetto F, et al
    Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24117.
    PubMed     Abstract available


  119. ZHENG X, Xu H, Gong L, Cao D, et al
    Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation.
    Prostate. 2021 Mar 12. doi: 10.1002/pros.24113.
    PubMed     Abstract available


  120. ATEEQ B, Kunju LP, Carskadon SL, Pandey SK, et al
    Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Prostate. 2021 Mar 8. doi: 10.1002/pros.24111.
    PubMed    


  121. SWANSON GP, Lenz L, Stone S, Cohen T, et al
    Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
    Prostate. 2021;81:261-267.
    PubMed     Abstract available


  122. TAN YG, Khalid F, Huang HH, Chen K, et al
    Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
    Prostate. 2021;81:242-251.
    PubMed     Abstract available


  123. LI Y, Ge C, Franceschi RT
    Role of Runx2 in prostate development and stem cell function.
    Prostate. 2021;81:231-241.
    PubMed     Abstract available


    February 2021
  124. SHENDEROV E, Boudadi K, Fu W, Wang H, et al
    Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Prostate. 2021 Feb 26. doi: 10.1002/pros.24110.
    PubMed     Abstract available


  125. WETTSTEIN MS, David LA, Pazhepurackel C, Qureshi AA, et al
    Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
    Prostate. 2021 Feb 18. doi: 10.1002/pros.24105.
    PubMed     Abstract available


  126. TAO LJ, Pan XY, Wang JW, Zhang L, et al
    Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes prostate cancer progression by upregulating TGF-alpha expression.
    Prostate. 2021 Feb 8. doi: 10.1002/pros.24102.
    PubMed     Abstract available


  127. LEE JM, Kim U, Yang H, Ryu B, et al
    TALEN-mediated generation of Nkx3.1 knockout rat model.
    Prostate. 2021;81:182-193.
    PubMed     Abstract available


    January 2021
  128. NAITO R, Kano H, Shimada T, Makino T, et al
    A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Prostate. 2021 Jan 25. doi: 10.1002/pros.24106.
    PubMed     Abstract available


  129. EMAM A, Hermann G, Attwood K, Ji W, et al
    Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
    Prostate. 2021 Jan 20. doi: 10.1002/pros.24089.
    PubMed     Abstract available


  130. VLACHOSTERGIOS PJ, Niaz MJ, Skafida M, Mosallaie SA, et al
    Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted beta-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jan 19. doi: 10.1002/pros.24104.
    PubMed     Abstract available


  131. LIU JM, Lin CC, Chen MF, Liu KL, et al
    Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
    Prostate. 2021 Jan 4. doi: 10.1002/pros.24096.
    PubMed     Abstract available


  132. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    PubMed     Abstract available


    December 2020
  133. IMAMURA R, Kitagawa S, Kubo T, Irie A, et al
    Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Prostate. 2020 Dec 24. doi: 10.1002/pros.24090.
    PubMed     Abstract available


  134. COUGHLIN SS, Vernon M, Klaassen Z, Tingen MS, et al
    Knowledge of prostate cancer among African American men: A systematic review.
    Prostate. 2020 Dec 23. doi: 10.1002/pros.24097.
    PubMed     Abstract available


  135. KAZUNO S, Fujimura T, Fujime M, Miura Y, et al
    O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.
    Prostate. 2020 Dec 21. doi: 10.1002/pros.24094.
    PubMed     Abstract available


  136. ZHANG Y, Mou Y, Liang C, Zhu S, et al
    Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
    Prostate. 2020 Dec 18. doi: 10.1002/pros.24092.
    PubMed     Abstract available


  137. ZHOU Y, Mai Z, Yan W, Chen Y, et al
    The characteristics and spatial distributions of prostate cancer in autopsy specimens.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24091.
    PubMed     Abstract available


  138. ZHANG Y, Guo Z, Du T, Chen J, et al
    Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24093.
    PubMed    


  139. SHEIKHBAHAEI S, Reyes DK, Rowe SP, Pienta KJ, et al
    CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer.
    Prostate. 2020 Dec 1. doi: 10.1002/pros.24088.
    PubMed     Abstract available


  140. GREENLAND NY, Cowan JE, Chan E, Carroll PR, et al
    Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
    Prostate. 2020;80:1421-1428.
    PubMed     Abstract available


  141. LI W, Bicak M, Sjoberg DD, Vertosick E, et al
    Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
    Prostate. 2020;80:1405-1412.
    PubMed     Abstract available


    November 2020
  142. SHIH HJ, Fang SC, An L, Shao YJ, et al
    Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.
    Prostate. 2020 Nov 5. doi: 10.1002/pros.24087.
    PubMed     Abstract available


  143. YAMOAH K, Lal P, Awasthi S, Naghavi AO, et al
    TMPRSS2-ERG fusion impact anterior tumor location in men with prostate cancer.
    Prostate. 2020 Nov 3. doi: 10.1002/pros.24086.
    PubMed     Abstract available


  144. DEEK M, Lilleby W, Vaage V, Hole KH, et al
    Impact of radiation dose on recurrence in high-risk prostate cancer patients.
    Prostate. 2020;80:1322-1327.
    PubMed     Abstract available


  145. BLACK MH, Li S, LaDuca H, Lo MT, et al
    Validation of a prostate cancer polygenic risk score.
    Prostate. 2020;80:1314-1321.
    PubMed     Abstract available


    October 2020
  146. JARRARD D, Filon M, Huang W, Havighurst T, et al
    A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
    Prostate. 2020 Oct 23. doi: 10.1002/pros.24076.
    PubMed     Abstract available


  147. YANG Y, Attwood K, Bshara W, Mohler JL, et al
    High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24068.
    PubMed     Abstract available


  148. MIYAHIRA AK, Soule HR
    The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24083.
    PubMed     Abstract available


  149. WASHINGTON SL 3RD, Cowan JE, Herlemann A, Zuniga KB, et al
    Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Prostate. 2020 Oct 19. doi: 10.1002/pros.24085.
    PubMed     Abstract available


  150. AMELOT A, Terrier LM, Le Nail LR, Cristini J, et al
    Spine metastasis in patients with prostate cancer: Survival prognosis assessment.
    Prostate. 2020 Oct 16. doi: 10.1002/pros.24084.
    PubMed     Abstract available


  151. IWAMOTO H, Izumi K, Shimada T, Kano H, et al
    Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
    Prostate. 2020 Oct 13. doi: 10.1002/pros.24082.
    PubMed     Abstract available


  152. DING Y, Lee M, Gao Y, Bu P, et al
    Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance.
    Prostate. 2020 Oct 6. doi: 10.1002/pros.24081.
    PubMed     Abstract available


  153. HERTZOG JR, Zhang Z, Bignan G, Connolly PJ, et al
    AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
    Prostate. 2020;80:1223-1232.
    PubMed     Abstract available


  154. MONTES M, MacKenzie L, McAllister MJ, Roseweir A, et al
    Determining the prognostic significance of IKKalpha in prostate cancer.
    Prostate. 2020;80:1188-1202.
    PubMed     Abstract available


    September 2020
  155. VICIER C, Ravi P, Kwak L, Werner L, et al
    Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Prostate. 2020 Sep 28. doi: 10.1002/pros.24079.
    PubMed     Abstract available


  156. OMRI N, Kamil M, Alexander K, Alexander K, et al
    Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Prostate. 2020 Sep 24. doi: 10.1002/pros.24078.
    PubMed     Abstract available


  157. LEE BS, Chu SY, Jung WJ, Jeong HJ, et al
    (18) F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
    Prostate. 2020 Sep 22. doi: 10.1002/pros.24062.
    PubMed     Abstract available


  158. VILSON FL, Li S, Brooks JD, Eisenberg ML, et al
    Sudden PSA rise to >/=20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
    Prostate. 2020 Sep 21. doi: 10.1002/pros.24075.
    PubMed     Abstract available


  159. HARSHMAN LC, Wang VX, Hamid AA, Santone G, et al
    Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Prostate. 2020 Sep 19. doi: 10.1002/pros.24074.
    PubMed     Abstract available


  160. NAITO Y, Kato M, Kawanishi H, Yuguchi Y, et al
    The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Prostate. 2020 Sep 11. doi: 10.1002/pros.24069.
    PubMed     Abstract available


  161. DUBEY B, Jackson M, Zeigler-Johnson C, Devarajan K, et al
    Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24067.
    PubMed     Abstract available


  162. ZHANG M, Wang Q, Sun X, Yin Q, et al
    beta2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24060.
    PubMed     Abstract available


  163. KAUR H, Samarska I, Lu J, Faisal F, et al
    Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Prostate. 2020;80:1012-1023.
    PubMed     Abstract available


  164. ANGEL PM, Spruill L, Jefferson M, Bethard JR, et al
    Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
    Prostate. 2020;80:1071-1086.
    PubMed     Abstract available


    August 2020
  165. MIYAHIRA AK, Pienta KJ, Babich JW, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
    Prostate. 2020 Aug 31. doi: 10.1002/pros.24056.
    PubMed     Abstract available


  166. MCALLISTER M, Constancio V, Patek S, Gan H, et al
    Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer.
    Prostate. 2020 Aug 26. doi: 10.1002/pros.24064.
    PubMed     Abstract available


  167. WIGGINS EK, Oyekunle T, Howard LE, Markt SC, et al
    Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.
    Prostate. 2020 Aug 24. doi: 10.1002/pros.24052.
    PubMed     Abstract available


  168. LIU W, Hou J, Petkewicz J, Na R, et al
    Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
    Prostate. 2020 Aug 17. doi: 10.1002/pros.24057.
    PubMed     Abstract available


  169. SHORE ND, Drake CG, Lin DW, Ryan CJ, et al
    Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
    Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
    PubMed     Abstract available


  170. DI BELLA CM, Howard LE, Oyekunle T, De Hoedt AM, et al
    Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
    Prostate. 2020 Aug 7. doi: 10.1002/pros.24054.
    PubMed     Abstract available


  171. SIMONS BW, Dalrymple S, Rosen M, Zheng L, et al
    A hemi-spleen injection model of liver metastasis for prostate cancer.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24055.
    PubMed     Abstract available


  172. NAEEM A, Dakshanamurthy S, Walthieu H, Parasido E, et al
    Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24050.
    PubMed     Abstract available


    July 2020
  173. AHMED ME, Andrews JR, Alamiri J, Higa J, et al
    Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
    Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.
    PubMed     Abstract available


  174. NANDA JS, Awadallah WN, Kohrt SE, Popovics P, et al
    Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Prostate. 2020 Jul 21. doi: 10.1002/pros.24019.
    PubMed     Abstract available


  175. FERRARI MG, Ganaie AA, Shabenah A, Mansini AP, et al
    Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients.
    Prostate. 2020 Jul 20. doi: 10.1002/pros.24018.
    PubMed     Abstract available


  176. DEE EC, Nezolosky MD, Chipidza FE, Arega MA, et al
    Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
    Prostate. 2020 Jul 13. doi: 10.1002/pros.24041.
    PubMed     Abstract available


  177. ABUDUREXITI M, Zhu W, Wang Y, Wang J, et al
    Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Prostate. 2020 Jul 10. doi: 10.1002/pros.24027.
    PubMed     Abstract available


  178. ERICKSON AM, Lokman U, Lahdensuo K, Tornberg S, et al
    PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
    Prostate. 2020 Jul 7. doi: 10.1002/pros.24040.
    PubMed     Abstract available


  179. ZHAN B, Huang L, Chen Y, Ye W, et al
    miR-196a-mediated downregulation of p27(kip1) protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24036.
    PubMed     Abstract available


  180. FEDERER-GSPONER JR, Muller DC, Zellweger T, Eggimann M, et al
    Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24039.
    PubMed     Abstract available


  181. QIN C, Sheng Z, Huang X, Tang J, et al
    Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24042.
    PubMed     Abstract available


  182. BONK S, Kluth M, Jansen K, Hube-Magg C, et al
    Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24038.
    PubMed     Abstract available


  183. TANG M, Gao S, Zhang L, Liu B, et al
    Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Prostate. 2020;80:742-752.
    PubMed     Abstract available


  184. RINELLA L, Pizzo B, Frairia R, Delsedime L, et al
    Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
    Prostate. 2020 Jul 1. doi: 10.1002/pros.24037.
    PubMed     Abstract available


    June 2020
  185. CHEN Y, Li X, Mamouni K, Yang Y, et al
    Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer.
    Prostate. 2020 Jun 19. doi: 10.1002/pros.24032.
    PubMed     Abstract available


  186. MAESHIGE N, Kitagawa K, Yamasaki S, Ishii A, et al
    Can ultrasound irradiation be a therapeutic option for prostate cancer?
    Prostate. 2020 Jun 18. doi: 10.1002/pros.24030.
    PubMed     Abstract available


  187. BEGEMANN D, Wang Y, Yang W, Kyprianou N, et al
    Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Prostate. 2020 Jun 16. doi: 10.1002/pros.24015.
    PubMed     Abstract available


  188. WANG K, Chen Z, Shi J, Feng Y, et al
    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
    Prostate. 2020 Jun 15. doi: 10.1002/pros.24029.
    PubMed     Abstract available


  189. TAYLOR RA, Farrelly SG, Clark AK, Watt MJ, et al
    Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice.
    Prostate. 2020 Jun 10. doi: 10.1002/pros.24024.
    PubMed     Abstract available


  190. ELHODAKY M, Hong LK, Kadkol S, Diamond AM, et al
    Selenium-binding protein 1 alters energy metabolism in prostate cancer cells.
    Prostate. 2020 Jun 8. doi: 10.1002/pros.24028.
    PubMed     Abstract available


  191. CHADID S, Barber JR, Nelson WG, Gurel B, et al
    The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24023.
    PubMed     Abstract available


  192. CARSON JJK, Di Lena MA, Berman DM, Siemens DR, et al
    Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24025.
    PubMed     Abstract available


  193. RII J, Sakamoto S, Yamada Y, Takeshita N, et al
    Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Prostate. 2020 Jun 5. doi: 10.1002/pros.24016.
    PubMed     Abstract available


  194. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2020;80:727.
    PubMed    


  195. OJALILL M, Virtanen N, Rappu P, Siljamaki E, et al
    Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins.
    Prostate. 2020;80:715-726.
    PubMed     Abstract available


  196. ITSUMI M, Shiota M, Sekino Y, Ushijima M, et al
    High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
    Prostate. 2020 Jun 1. doi: 10.1002/pros.24022.
    PubMed     Abstract available


  197. ELSHAFAE SM, Dirksen WP, Alasonyalilar-Demirer A, Breitbach J, et al
    Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Prostate. 2020;80:698-714.
    PubMed     Abstract available


  198. PALANGMONTHIP W, Wu R, Tarima S, Bobholz SA, et al
    Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
    Prostate. 2020;80:687-697.
    PubMed     Abstract available


    May 2020
  199. LINDER A, Larsson K, Welen K, Damber JE, et al
    RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Prostate. 2020 May 25. doi: 10.1002/pros.23994.
    PubMed     Abstract available


  200. TABEI T, Taguri M, Sakai N, Koh H, et al
    Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
    Prostate. 2020 May 20. doi: 10.1002/pros.23997.
    PubMed     Abstract available


  201. SHI X, Sun J, Li H, Lin H, et al
    Antitumor efficacy of interferon-gamma-modified exosomal vaccine in prostate cancer.
    Prostate. 2020 May 19. doi: 10.1002/pros.23996.
    PubMed     Abstract available


  202. HOU Y, Li H, Huo W
    THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
    Prostate. 2020 May 18. doi: 10.1002/pros.23989.
    PubMed     Abstract available


  203. LIU Z, Murphy SF, Huang J, Zhao L, et al
    A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Prostate. 2020 May 14. doi: 10.1002/pros.23993.
    PubMed     Abstract available


  204. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study.
    Prostate. 2020 May 5. doi: 10.1002/pros.23991.
    PubMed     Abstract available


  205. LIU S, Liu F, Zhang B, Yan P, et al
    CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion.
    Prostate. 2020 May 1. doi: 10.1002/pros.23990.
    PubMed     Abstract available


  206. SU X, Long Q, Bo J, Shi Y, et al
    Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
    Prostate. 2020;80:508-517.
    PubMed     Abstract available


  207. GLEAVE AM, Ci X, Lin D, Wang Y, et al
    A synopsis of prostate organoid methodologies, applications, and limitations.
    Prostate. 2020;80:518-526.
    PubMed     Abstract available


  208. GREENLAND NY, Cowan JE, Zhang L, Carroll PR, et al
    Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Prostate. 2020;80:653-659.
    PubMed     Abstract available


    April 2020
  209. SEBBEN M, Tafuri A, Porcaro AB, Artibani W, et al
    Response to: Bando et al. Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histological and molecular analyses.
    Prostate. 2020 Apr 23. doi: 10.1002/pros.23987.
    PubMed    


  210. LI X, Jiao M, Hu J, Qi M, et al
    miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Prostate. 2020 Apr 15. doi: 10.1002/pros.23979.
    PubMed     Abstract available


  211. CHENG Y, Wang D, Jiang J, Huang W, et al
    Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Prostate. 2020 Apr 13. doi: 10.1002/pros.23976.
    PubMed     Abstract available


    March 2020
  212. LEU WJ, Wang CT, Hsu JL, Chen IS, et al
    Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na(+) /K(+) -ATPase internalization and tubulin acetylation.
    Prostate. 2020;80:305-318.
    PubMed     Abstract available


  213. WU Z, Wang K, Yang Z, Pascal LE, et al
    A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function.
    Prostate. 2020;80:319-328.
    PubMed     Abstract available


    February 2020
  214. ERDEM S, Verep S, Bagbudar S, Ozluk Y, et al
    The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
    Prostate. 2020;80:225-234.
    PubMed     Abstract available


  215. FAGERLAND ST, Hill DK, van Wamel A, de Lange Davies C, et al
    Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
    Prostate. 2020;80:186-197.
    PubMed     Abstract available


  216. TAYLOR AS, Morgan TM, Wallington DG, Chinnaiyan AM, et al
    Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Prostate. 2020;80:146-152.
    PubMed     Abstract available


  217. THOMAS-JARDIN SE, Dahl H, Kanchwala MS, Ha F, et al
    RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Prostate. 2020;80:133-145.
    PubMed     Abstract available


  218. WANG R, Lewis MS, Lyu J, Zhau HE, et al
    Cancer-stromal cell fusion as revealed by fluorescence protein tracking.
    Prostate. 2020;80:274-283.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: